跳转至内容
Merck
CN

[New direct oral anticoagulants and venous thromboprophylaxis].

La Revue du praticien (2013-10-31)
Su Emmanuelle Degirmenci, Annick Steib
摘要

The new direct oral anticoagulants currently available are dabigatran, rivaroxaban and apixaban. These three drugs have been labeled in France for the prevention of venous thromboembolism after elective orthopaedic surgery including total hip or knee arthroplastly. Rivaroxaban is also labeled for the secondary prevention of thrombosis recurrence following an initial acute event. Pharmacologic properties of these drugs are reminded as well as the results of the main studies having conducted to their approval.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
β-丙氨酸, 99%
Sigma-Aldrich
β-丙氨酸, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
β-丙氨酸, BioXtra, ≥99.0% (NT)
Sigma-Aldrich
β-丙氨酸, BioUltra, ≥99.0% (NT)